Chronic Gout
Conditions
Brief summary
This is one of two replicate randomized, double-blind, placebo-controlled, parallel arm trials to determine the safety and efficacy of two different dose levels of SEL-212 compared to placebo. 112 and 153 patients, stratified as to the presence or absence of tophi, were randomized in a 1:1:1 allocation ratio prior to Baseline to receive treatment with one of two dose levels of SEL-212 or placebo every 28 days for approximately 6 months in each trial respectively (SEL-212/301 and SEL-212/302). Analysis of primary and key efficacy was performed at Day 28 of Treatment Period 6. Safety was monitored throughout the study.
Detailed description
This is one of two replicate randomized, double-blind, placebo-controlled, parallel arm trials to determine the safety and efficacy of two different dose levels of SEL-212 compared to placebo. 112 and 153 patients, stratified as to the presence or absence of tophi, were randomized in a 1:1:1 allocation ratio prior to Baseline to receive treatment with one of two dose levels of SEL-212 or placebo every 28 days for approximately 6 months in each trial respectively (SEL-212/301 and SEL-212/302). The SEL-212 doses differed as to the SEL-110.36 component. Participants received SEL-037 administered at a dose of 0.2 mg/kg via intravenous (IV) infusion immediately after receiving SEL-110.36 at a dose of either 0.1 mg/kg (SEL-212 low-dose) or 0.15 mg/kg (SEL-212 high-dose) via IV infusion. The placebo consisted of normal saline. Upon completion of the 6-month double-blinded, placebo-controlled portion of the study, SEL-212/301 continued in a blinded, placebo-controlled 6-month extension. This provided up to 12 months of continuous treatment with SEL-212 in a placebo controlled fashion. Efficacy assessments were conducted at intervals that are appropriate to determine treatment effect with samples for the primary endpoint drawn during Treatment Period 6. Safety was monitored throughout the study with an independent data safety monitoring board (DSMB).
Interventions
DRUGSEL-212 low-dose
IV infusion of SEL-212 low-dose every 28 days for a total of up to 12 infusions
IV infusion of SEL-212 high-dose every 28 days for a total of up to 12 infusions
OTHERNormal Saline
IV infusion of Normal Saline every 28 days for a total of up to 12 infusions
Sponsors
Swedish Orphan Biovitrum
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
19 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Has negative results of an FDA Emergency Use Authorized COVID-19 molecular assay for detection of SARS-CoV-2 RNA from a nasal or oropharyngeal specimen; 2. History of symptomatic gout defined as: 1. ≥ 3 gout flares within 18 months of Screening or 2. Presence of ≥ 1 gout tophus or 3. Current diagnosis of gouty arthritis 3. At the Screening Visit: male age 21 - 80 years, inclusive, or female of non-childbearing potential age 21-80 years, inclusive, where nonchildbearing potential is defined as: a. \> 6 weeks after hysterectomy with or without surgical bilateral salpingooperhectony or b. Post-menopausal (\> 24 months of natural amenorrhea or in the absence of \>24 months of amenorrhea, one documented confirmatory FSH measurement) 4. Has chronic refractory gout defined as having failed to normalize sUA and whose signs and symptoms are inadequately controlled with any of the xanthine oxidase inhibitors, or for whom these drugs are contraindicated for the patient; 5. Has at the Screening Visit SUA ≥ 7 mg/dL 6. Negative serology for HIV-1/-2 and negative antigen to hepatitis B and negative antibodies to hepatitis C;
Exclusion criteria
1. Has a history of anaphylaxis, severe allergic reactions, or severe atopy; 2. Has a history of any allergy to pegylated products, including, but not limited to pegloticase (Krystexxa®), peginterferon alfa-2a (Pegasys®), peginterferon alfa-2b (PegIntron®), pegfilgrastim (Neulasta®), pegaptanib (Macugen®), pegaspargase (Oncaspar®), pegademase (Adagen®), peg-epoetin beta (Mircera®), pegvisomant (Somavert®) certolizumab pegol (Cimzia®), naloxegol (Movantik®), peginesatide (Omontys®), and doxorubicin liposome (Doxil®); 3. Is taking and cannot discontinue known major CYP3A4/P-gp inhibitors or major CYP3A4/P-gp inducers at least 14 days before dosing. Patients must remain off these medications for the duration of the study, including natural products such as St. John's Wort or grapefruit juice. 4. Is taking drugs known to interact with rapamycin (sirolimus - Rapamune®) such as cyclosporine, diltiazem, erythromycin, ketoconazole, posaconazole, voriconazole, itraconazole, rifampin, verapamil unless they are stopped 14 days prior to dosing and will not be used/prescribed during the trial. 5. Had major surgery within 3 months of initial screening. 6. Had a gout flare during Screening that was resolved for less than 1 week prior to first treatment with study drug (exclusive of chronic synovitis/arthritis) unless the patient has a history of inter-flare intervals of \< 1 week. 7. Has uncontrolled diabetes at Screening with HbA1c ≥ 8.5%; 8. Has fasting Screening glucose \> 240 mg/dL; 9. Has fasting Screening triglyceride \> 500 mg/dL; 10. Has fasting Screening low-density lipoprotein (LDL) \> 200 mg/dL; 11. Has glucose-6-phosphate dehydrogenase (G6PD) deficiency; 12. Has uncontrolled hypertension defined as blood pressure \> 170/100 mmHg at Screening and 1 week prior to dosing 13. Individual laboratory values which are exclusionary * White blood cell count (WBC) \< 3.0 x109/L * Serum aspartate aminotransferase (AST) or alanine amino transferase (ALT) \> 3x upper limit of normal (ULN) in the absence of known active liver disease * Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m2 * Urine albumin creatinine ratio (UACR) \> 30 mg/g * Hemoglobin (Hgb) \< 9 g/dL * Serum phosphate \< 2.0 mg/dL 14. Is receiving ongoing treatment for arrhythmia, including placement of an implantable defibrillator, unless considered stable and on active treatment; 15. Has evidence of unstable cardiovascular disease or unstable cerebrovascular vascular disease. This includes patients who have had a cardiac/vascular event(s) in the last 3 months including heart attack, stroke or vascular bypass surgery or patients who are deemed, by their physician or PI, to have active cardiovascular, cerebrovascular or peripheral vascular symptoms/disease inadequately controlled by medication; 16. Has congestive heart failure, New York Heart Association Class III or IV; 17. Unless clinically stable and/or appropriately treated, electrocardiogram (ECG) with evidence of clinically significant arrhythmia or other abnormalities that, in the opinion of the investigator, are consistent with significant underlying cardiac disease; 18. History of significant hematological disorders within 5 years or autoimmune disorders, and/or patient is currently immunosuppressed or immunocompromised; 19. Prior exposure to any experimental or marketed uricase (e.g., rasburicase (Elitek, Fasturtec), pegloticase (Krystexxa®), pegadricase (SEL 37)) 20. Patient has received a live vaccine in the previous 6 months. 21. Patient is planning to receive any live vaccine during the study. 22. History of malignancy within the last 5 years other than basal skin cancer; 23. Patients with a documented history of moderate or severe alcohol or substance use disorder within the 12 months prior to randomization. 24. History of or evidence of clinically severe interstitial lung disease 25. Immunocompromised state, regardless of etiology
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of Participants Who Achieved and Maintained Reduction in Serum Uric Acid (sUA) < 6 Milligrams Per Deciliter (mg/dL) for At Least 80% of The Time During Treatment Period 6 (Month 6) | Month 6 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage Change From Baseline in Mean sUA | Baseline, Up to 6 months | — |
| Change From Baseline in the Physical Component Summary Score of the Short Form Health Survey (SF-36) | Baseline, Up to 6 months | The SF-36 is a 36-item scale constructed to survey health status and quality of life (QoL). The SF-36 assesses 8 health concepts, which are the weighted sums of the questions in their section: limitations in physical activities because of health problems; limitations in social activities because of physical or emotional problems; limitations in usual role activities because of physical health problems; bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities because of emotional problems; vitality (energy and fatigue); and general health perceptions. Each scale was directly transformed into a 0-100 scale, and the total average scores were calculated across the 8 health concepts. The 8 domains contributed to physical component summary and mental component summary scores. Total scores for the physical component summary score ranged from 0-100, with a higher score indicating better health outcomes. |
| Proportion of Participants With at Least Partial Response (PR) (as Best Response) in Overall Tophus Response Evaluation in Participants With Tophi at Baseline | Baseline up to 6 months | Baseline photographs of the hands and feet of each participant were obtained using a standardized method in all participants together with photographs of up to 2 other representative sites of tophaceous disease. The baseline photographs were assessed by three independent reviewers to prospectively identify sites of tophaceous disease present at the start of treatment. Up to 5 tophi in the photographs were chosen by the reviewers for measurement over the course of therapy. The reviewers assessed the photographs for size of each target tophus using image analysis software. At least PR was defined as at least a 50% decrease in the area of at least one tophus, and includes participants with complete response (CR). Data are presented for the proportion of participants with at least PR (as best response). |
| Proportion of Participants Who Achieved and Maintained Reduction of sUA < 6 mg/dL for at Least 80% of the Time During Month 6 in the Subset of Participants With Tophi at Baseline | Baseline up to 6 months | The number of responders in the subgroup of Intent-to-Treat participants with tophi at baseline divided by the number of Intent-to-Treat participants with tophi at baseline. |
| Change From Baseline in Mean sUA | Baseline, Up to 6 months | — |
| Change From Baseline to Month 6 in the Total Score of the Health Assessment Questionnaire Disability Index (HAQ-DI) | Baseline, Up to 6 months | The HAQ-DI assesses fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both the upper and lower extremities. It includes 20 items in 8 categories: activity, arising, dressing and grooming, eating, grip, hygiene, reach and walking. Scoring within each section was on a 4-point Likert scale from 0 (without any difficulty) to 3 (unable to do), with higher score showing more disability. The average of the 8 category scores was reported as the HAQ-DI total score on a scale of 0 to 3. A decrease in HAQ-DI score from baseline indicated an improvement in the participant's condition. |
| Incidence of Gout Flare During Treatment Periods 1-6 (Months 1-6) | Months 1-6 | Gout flare was assessed as part of adverse event (AE) collection. Gout flares were assessed during the Treatment Phase using a validated definition of flares in participants with established gout. A gout flare (per Gaffo et al. 2018) was defined as the fulfillment of at least 3 of the following 4 criteria: 1. Participant-defined gout flare, 2. Pain at rest score of \>3 on a 0-10-point numerical rating scale, 3. Presence of at least 1 swollen joint, 4. Presence of at least 1 warm joint. Data are presented for the LS mean incidence per month of gout flares during Treatment Periods 1-6 (Months 1-6). A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. |
| Incidence of Gout Flare During Treatment Periods 1-3 (Months 1-3) | Months 1-3 | Gout flare was assessed as part of adverse event (AE) collection. Gout flares were assessed during the Treatment Phase using a validated definition of flares in participants with established gout. A gout flare (per Gaffo et al. 2018) was defined as the fulfillment of at least 3 of the following 4 criteria: 1. Participant-defined gout flare, 2. Pain at rest score of \>3 on a 0-10-point numerical rating scale, 3. Presence of at least 1 swollen joint, 4. Presence of at least 1 warm joint. Data are presented for the LS mean incidence per month of gout flares during Treatment Periods 1-3 (Months 1-3). A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. |
| Change From Baseline to Month 6 in Number of Tender Joints | Baseline, Up to 6 months | Tender and/or swollen joints were counted. The following joints were assessed: metacarpophalangeal, proximal interphalangeal, and distal interphalangeal joints of the hands; the metatarsophalangeal and interphalangeal joints of the feet; shoulder, elbow, wrist, knee, ankle, tarsus, sternoclavicular, and acromioclavicular joints. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| SEL-212A (Low-dose) SEL-212 is comprised of 2 components: SEL-037 and SEL-110. Participants received SEL-037 administered at a dose of 0.2 milligrams per kilogram (mg/kg) via intravenous (IV) infusion immediately after receiving SEL-110 at a dose of 0.1 mg/kg (SEL-212A) every 28 days for approximately six months during the double-blind treatment phase.
After completion of the double-blind treatment phase, participants continued into the double-blind extension phase. In this phase, participants continued in the identical study treatment group (SEL-212A \[low-dose\]) for six additional doses, every 28 days, lasting up to approximately an additional six months. | 37 |
| SEL-212B (High-dose) SEL-212 is comprised of 2 components: SEL-037 and SEL-110. Participants received SEL-037 administered at a dose of 0.2 mg/kg via IV infusion immediately after receiving SEL-110 at a dose of 0.15 mg/kg (SEL-212B) every 28 days for approximately six months during the double-blind treatment phase.
After completion of the double-blind treatment phase, participants continued into the double-blind extension phase. In this phase, participants continued in the identical study treatment group (SEL-212A \[high-dose\]) for six additional doses, every 28 days, lasting up to approximately an additional six months. | 38 |
| Placebo Participants received placebo (normal saline) via IV infusion every 28 days for approximately six months during the double-blind treatment phase.
After completion of the double-blind treatment phase, participants continued into the double-blind extension phase. In this phase, participants continued in the identical study treatment group (placebo) for six additional doses, every 28 days, lasting up to approximately an additional six months. | 37 |
| Total | 112 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Extension Phase | Adverse Event | 0 | 0 | 1 |
| Extension Phase | Death | 0 | 1 | 0 |
| Extension Phase | Lost to Follow-up | 1 | 1 | 1 |
| Extension Phase | Other than Specified | 4 | 0 | 1 |
| Extension Phase | Sponsor Decision | 0 | 1 | 0 |
| Extension Phase | Withdrawal by Subject | 3 | 1 | 1 |
| Treatment Phase | Adverse Event | 0 | 1 | 1 |
| Treatment Phase | Lost to Follow-up | 1 | 2 | 5 |
| Treatment Phase | Other than Specified | 1 | 0 | 2 |
| Treatment Phase | Physician Decision | 2 | 0 | 0 |
| Treatment Phase | Withdrawal by Subject | 6 | 8 | 3 |
Baseline characteristics
| Characteristic | SEL-212A (Low-dose) | SEL-212B (High-dose) | Placebo | Total |
|---|---|---|---|---|
| Age, Continuous | 55.4 years STANDARD_DEVIATION 10.55 | 53.6 years STANDARD_DEVIATION 11.99 | 53.6 years STANDARD_DEVIATION 10.57 | 54.2 years STANDARD_DEVIATION 11 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 14 Participants | 6 Participants | 10 Participants | 30 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 23 Participants | 32 Participants | 27 Participants | 82 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 0 Participants | 3 Participants | 4 Participants |
| Race (NIH/OMB) Black or African American | 6 Participants | 9 Participants | 7 Participants | 22 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants | 2 Participants | 0 Participants | 3 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 4 Participants | 5 Participants |
| Race (NIH/OMB) White | 28 Participants | 27 Participants | 22 Participants | 77 Participants |
| Sex: Female, Male Female | 2 Participants | 3 Participants | 0 Participants | 5 Participants |
| Sex: Female, Male Male | 35 Participants | 35 Participants | 37 Participants | 107 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 37 | 1 / 38 | 0 / 37 |
| other Total, other adverse events | 31 / 37 | 29 / 38 | 27 / 37 |
| serious Total, serious adverse events | 10 / 37 | 5 / 38 | 2 / 37 |
Outcome results
Primary
Proportion of Participants Who Achieved and Maintained Reduction in Serum Uric Acid (sUA) < 6 Milligrams Per Deciliter (mg/dL) for At Least 80% of The Time During Treatment Period 6 (Month 6)
Time frame: Month 6
Population: Intent-to-Treat Set, which included all randomized and dosed participants, including participants with missing data that were multiple imputed. Participants were analyzed according to randomized treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SEL-212A (Low-dose) | Proportion of Participants Who Achieved and Maintained Reduction in Serum Uric Acid (sUA) < 6 Milligrams Per Deciliter (mg/dL) for At Least 80% of The Time During Treatment Period 6 (Month 6) | 0.48 proportion of participants |
| SEL-212B (High-dose) | Proportion of Participants Who Achieved and Maintained Reduction in Serum Uric Acid (sUA) < 6 Milligrams Per Deciliter (mg/dL) for At Least 80% of The Time During Treatment Period 6 (Month 6) | 0.56 proportion of participants |
| Placebo | Proportion of Participants Who Achieved and Maintained Reduction in Serum Uric Acid (sUA) < 6 Milligrams Per Deciliter (mg/dL) for At Least 80% of The Time During Treatment Period 6 (Month 6) | 0.04 proportion of participants |
p-value: <0.000197.5% CI: [0.23, 0.64]Mantel Haenszel
p-value: <0.000197.5% CI: [0.32, 0.73]Mantel Haenszel
Secondary
Change From Baseline in Mean sUA
Time frame: Baseline, Up to 6 months
Population: Intent-to-Treat Set, which included all randomized and dosed participants including participants with missing data that were multiple imputed. Participants were analyzed according to randomized treatment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| SEL-212A (Low-dose) | Change From Baseline in Mean sUA | -5.1 mg/dL | Standard Error 0.6 |
| SEL-212B (High-dose) | Change From Baseline in Mean sUA | -5.5 mg/dL | Standard Error 0.6 |
| Placebo | Change From Baseline in Mean sUA | 0.2 mg/dL | Standard Error 0.6 |
p-value: <0.00197.5% CI: [-7.18, -3.42]ANCOVA
p-value: <0.00197.5% CI: [-7.57, -3.7]ANCOVA
Secondary
Change From Baseline in the Physical Component Summary Score of the Short Form Health Survey (SF-36)
The SF-36 is a 36-item scale constructed to survey health status and quality of life (QoL). The SF-36 assesses 8 health concepts, which are the weighted sums of the questions in their section: limitations in physical activities because of health problems; limitations in social activities because of physical or emotional problems; limitations in usual role activities because of physical health problems; bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities because of emotional problems; vitality (energy and fatigue); and general health perceptions. Each scale was directly transformed into a 0-100 scale, and the total average scores were calculated across the 8 health concepts. The 8 domains contributed to physical component summary and mental component summary scores. Total scores for the physical component summary score ranged from 0-100, with a higher score indicating better health outcomes.
Time frame: Baseline, Up to 6 months
Population: Intent-to-Treat Set, which included all randomized and dosed participants including participants with missing data that were multiple imputed. Participants were analyzed according to randomized treatment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| SEL-212A (Low-dose) | Change From Baseline in the Physical Component Summary Score of the Short Form Health Survey (SF-36) | 7.4 score on a scale | Standard Error 1.8 |
| SEL-212B (High-dose) | Change From Baseline in the Physical Component Summary Score of the Short Form Health Survey (SF-36) | 4.8 score on a scale | Standard Error 1.7 |
| Placebo | Change From Baseline in the Physical Component Summary Score of the Short Form Health Survey (SF-36) | 3.0 score on a scale | Standard Error 1.8 |
p-value: 0.09Mixed Models Analysis
p-value: 0.472Mixed Models Analysis
Secondary
Change From Baseline to Month 6 in Number of Tender Joints
Tender and/or swollen joints were counted. The following joints were assessed: metacarpophalangeal, proximal interphalangeal, and distal interphalangeal joints of the hands; the metatarsophalangeal and interphalangeal joints of the feet; shoulder, elbow, wrist, knee, ankle, tarsus, sternoclavicular, and acromioclavicular joints.
Time frame: Baseline, Up to 6 months
Population: Intent-to-Treat Set, which included all randomized and dosed participants including participants with missing data that were multiple imputed. Participants were analyzed according to randomized treatment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| SEL-212A (Low-dose) | Change From Baseline to Month 6 in Number of Tender Joints | -2.1 tender joints | Standard Error 0.3 |
| SEL-212B (High-dose) | Change From Baseline to Month 6 in Number of Tender Joints | -1.4 tender joints | Standard Error 0.3 |
| Placebo | Change From Baseline to Month 6 in Number of Tender Joints | -1.9 tender joints | Standard Error 0.3 |
p-value: 0.51797.5% CI: [-1.1, 0.61]Mixed Models Analysis
p-value: 0.2397.5% CI: [-0.39, 1.28]Mixed Models Analysis
Secondary
Change From Baseline to Month 6 in the Total Score of the Health Assessment Questionnaire Disability Index (HAQ-DI)
The HAQ-DI assesses fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both the upper and lower extremities. It includes 20 items in 8 categories: activity, arising, dressing and grooming, eating, grip, hygiene, reach and walking. Scoring within each section was on a 4-point Likert scale from 0 (without any difficulty) to 3 (unable to do), with higher score showing more disability. The average of the 8 category scores was reported as the HAQ-DI total score on a scale of 0 to 3. A decrease in HAQ-DI score from baseline indicated an improvement in the participant's condition.
Time frame: Baseline, Up to 6 months
Population: Intent-to-Treat Set, which included all randomized and dosed participants including participants with missing data that were multiple imputed. Participants were analyzed according to randomized treatment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| SEL-212A (Low-dose) | Change From Baseline to Month 6 in the Total Score of the Health Assessment Questionnaire Disability Index (HAQ-DI) | -0.2 score on a scale | Standard Error 0.1 |
| SEL-212B (High-dose) | Change From Baseline to Month 6 in the Total Score of the Health Assessment Questionnaire Disability Index (HAQ-DI) | 0.0 score on a scale | Standard Error 0.1 |
| Placebo | Change From Baseline to Month 6 in the Total Score of the Health Assessment Questionnaire Disability Index (HAQ-DI) | -0.1 score on a scale | Standard Error 0.1 |
p-value: 0.2597.5% CI: [-0.35, 0.12]Mixed Models Analysis
p-value: 0.50697.5% CI: [-0.16, 0.29]Mixed Models Analysis
Secondary
Incidence of Gout Flare During Treatment Periods 1-3 (Months 1-3)
Gout flare was assessed as part of adverse event (AE) collection. Gout flares were assessed during the Treatment Phase using a validated definition of flares in participants with established gout. A gout flare (per Gaffo et al. 2018) was defined as the fulfillment of at least 3 of the following 4 criteria: 1. Participant-defined gout flare, 2. Pain at rest score of \>3 on a 0-10-point numerical rating scale, 3. Presence of at least 1 swollen joint, 4. Presence of at least 1 warm joint. Data are presented for the LS mean incidence per month of gout flares during Treatment Periods 1-3 (Months 1-3). A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Months 1-3
Population: Intent-to-Treat Set, which included all randomized and dosed participants including participants with missing data that were multiple imputed. Participants were analyzed according to randomized treatment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| SEL-212A (Low-dose) | Incidence of Gout Flare During Treatment Periods 1-3 (Months 1-3) | 0.4 gout flares/month | Standard Error 0.1 |
| SEL-212B (High-dose) | Incidence of Gout Flare During Treatment Periods 1-3 (Months 1-3) | 0.4 gout flares/month | Standard Error 0.1 |
| Placebo | Incidence of Gout Flare During Treatment Periods 1-3 (Months 1-3) | 0.3 gout flares/month | Standard Error 0.1 |
Comparison: Treatment Periods 1-3 (Months 1-3)p-value: 0.73197.5% CI: [-0.4, 0.54]ANOVA
Comparison: Treatment Periods 1-3 (Month 1-3)p-value: 0.58397.5% CI: [-0.35, 0.58]ANOVA
Secondary
Incidence of Gout Flare During Treatment Periods 1-6 (Months 1-6)
Gout flare was assessed as part of adverse event (AE) collection. Gout flares were assessed during the Treatment Phase using a validated definition of flares in participants with established gout. A gout flare (per Gaffo et al. 2018) was defined as the fulfillment of at least 3 of the following 4 criteria: 1. Participant-defined gout flare, 2. Pain at rest score of \>3 on a 0-10-point numerical rating scale, 3. Presence of at least 1 swollen joint, 4. Presence of at least 1 warm joint. Data are presented for the LS mean incidence per month of gout flares during Treatment Periods 1-6 (Months 1-6). A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Months 1-6
Population: Intent-to-Treat Set, which included all randomized and dosed participants including participants with missing data that were multiple imputed. Participants were analyzed according to randomized treatment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| SEL-212A (Low-dose) | Incidence of Gout Flare During Treatment Periods 1-6 (Months 1-6) | 0.2 gout flares/month | Standard Error 0.1 |
| SEL-212B (High-dose) | Incidence of Gout Flare During Treatment Periods 1-6 (Months 1-6) | 0.4 gout flares/month | Standard Error 0.1 |
| Placebo | Incidence of Gout Flare During Treatment Periods 1-6 (Months 1-6) | 0.3 gout flares/month | Standard Error 0.1 |
p-value: 0.65397.5% CI: [-0.55, 0.37]ANOVA
p-value: 0.62997.5% CI: [-0.36, 0.56]ANOVA
Secondary
Percentage Change From Baseline in Mean sUA
Time frame: Baseline, Up to 6 months
Population: Intent-to-Treat Set, which included all randomized and dosed participants including participants with missing data that were multiple imputed. Participants were analyzed according to randomized treatment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| SEL-212A (Low-dose) | Percentage Change From Baseline in Mean sUA | -58.7 percentage change | Standard Error 8 |
| SEL-212B (High-dose) | Percentage Change From Baseline in Mean sUA | -64.2 percentage change | Standard Error 7.1 |
| Placebo | Percentage Change From Baseline in Mean sUA | 5.6 percentage change | Standard Error 6.8 |
p-value: <0.00197.5% CI: [-87.85, -40.85]ANCOVA
p-value: <0.00197.5% CI: [-92.16, -47.35]ANCOVA
Secondary
Proportion of Participants Who Achieved and Maintained Reduction of sUA < 6 mg/dL for at Least 80% of the Time During Month 6 in the Subset of Participants With Tophi at Baseline
The number of responders in the subgroup of Intent-to-Treat participants with tophi at baseline divided by the number of Intent-to-Treat participants with tophi at baseline.
Time frame: Baseline up to 6 months
Population: Intent-to-Treat Set, which included all randomized and dosed participants, including participants with missing outcome measure data that were multiple imputed. Participants were analyzed according to randomized treatment. Here, overall number of participants analyzed = participants with tophi at baseline and evaluable data for the outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SEL-212A (Low-dose) | Proportion of Participants Who Achieved and Maintained Reduction of sUA < 6 mg/dL for at Least 80% of the Time During Month 6 in the Subset of Participants With Tophi at Baseline | 0.50 proportion of participants |
| SEL-212B (High-dose) | Proportion of Participants Who Achieved and Maintained Reduction of sUA < 6 mg/dL for at Least 80% of the Time During Month 6 in the Subset of Participants With Tophi at Baseline | 0.34 proportion of participants |
| Placebo | Proportion of Participants Who Achieved and Maintained Reduction of sUA < 6 mg/dL for at Least 80% of the Time During Month 6 in the Subset of Participants With Tophi at Baseline | 0.07 proportion of participants |
p-value: 0.003597.5% CI: [0.14, 0.72]Chi-squared
p-value: 0.042897.5% CI: [-0.02, 0.57]Chi-squared
Secondary
Proportion of Participants With at Least Partial Response (PR) (as Best Response) in Overall Tophus Response Evaluation in Participants With Tophi at Baseline
Baseline photographs of the hands and feet of each participant were obtained using a standardized method in all participants together with photographs of up to 2 other representative sites of tophaceous disease. The baseline photographs were assessed by three independent reviewers to prospectively identify sites of tophaceous disease present at the start of treatment. Up to 5 tophi in the photographs were chosen by the reviewers for measurement over the course of therapy. The reviewers assessed the photographs for size of each target tophus using image analysis software. At least PR was defined as at least a 50% decrease in the area of at least one tophus, and includes participants with complete response (CR). Data are presented for the proportion of participants with at least PR (as best response).
Time frame: Baseline up to 6 months
Population: Intent-to-Treat Set, which included all randomized and dosed participants, including participants with missing outcome measure data that were multiple imputed. Participants were analyzed according to randomized treatment. Here, overall number of participants analyzed = participants with tophi at baseline and evaluable data for the outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SEL-212A (Low-dose) | Proportion of Participants With at Least Partial Response (PR) (as Best Response) in Overall Tophus Response Evaluation in Participants With Tophi at Baseline | 1.00 proportion of participants |
| SEL-212B (High-dose) | Proportion of Participants With at Least Partial Response (PR) (as Best Response) in Overall Tophus Response Evaluation in Participants With Tophi at Baseline | 0.67 proportion of participants |
| Placebo | Proportion of Participants With at Least Partial Response (PR) (as Best Response) in Overall Tophus Response Evaluation in Participants With Tophi at Baseline | 0.42 proportion of participants |
p-value: 0.000397.5% CI: [0.25, 0.91]Chi-squared
p-value: 0.189597.5% CI: [-0.36, 0.86]Chi-squared